Apparent Abamectin 18 Miticide/Insecticide

AIRR Apparent Pty Ltd.

Chemwatch Hazard Alert Code: **4**

Chemwatch: **9656-76**
Version No: **2.1**
Safety Data Sheet according to Work Health and Safety Regulations (Hazardous Chemicals) 2023 and ADG requirements

Initial Date: **12/11/2026**
Revision Date: **12/11/2026**
Print Date: **23/11/2026**
L.GHS.AUS.EN.E

SECTION 1 Identification of the substance / mixture and of the company / undertaking

Product Identifier

Product name	Apparent Abamectin 18 Miticide/Insecticide
Chemical Name	Not Applicable
Synonyms	Not Available
Proper shipping name	PESTICIDE, LIQUID, TOXIC, N.O.S. (contains N-methyl-2-pyrrolidone and abamectin)
Chemical formula	Not Applicable
Other means of identification	Not Available

Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	A liquid agricultural insecticide and miticide. Use according to manufacturer's directions.

Details of the manufacturer or importer of the safety data sheet

Registered company name	**AIRR Apparent Pty Ltd.**
Address	15/16 Princes Street, Newport NSW 2106 Australia
Telephone	+61 3 5820 8400
Fax	Not Available
Website	www.apparent.com.au
Email	enquiries@apparentag.com.au

Emergency telephone number

Association / Organisation	**AIRR Apparent Pty Ltd.**
Emergency telephone number(s)	1800 033 111 (24 Hours)
Other emergency telephone number(s)	Not Available

SECTION 2 Hazards identification

Classification of the substance or mixture

COMBUSTIBLE LIQUID, regulated for storage purposes only

Poisons Schedule	S6
Classification [1]	Flammable Liquids Category 4, Acute Toxicity (Oral) Category 1, Acute Toxicity (Dermal) Category 3, Skin Corrosion/Irritation Category 2, Serious Eye Damage/Eye Irritation Category 2A, Acute Toxicity (Inhalation) Category 1, Specific Target Organ Toxicity - Single Exposure (Respiratory Tract Irritation) Category 3, Reproductive Toxicity Category 1A, Specific Target Organ Toxicity - Repeated Exposure Category 1, Hazardous to the Aquatic Environment Long-Term Hazard Category 1
Legend:	***1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI***

Label elements

Hazard pictogram(s)	
Signal word	**Danger**

Hazard statement(s)

Page 1 continued...

H227	Combustible liquid.
H300	Fatal if swallowed.
H311	Toxic in contact with skin.
H315	Causes skin irritation.
H319	Causes serious eye irritation.
H330	Fatal if inhaled.
H335	May cause respiratory irritation.
H360FD	May damage fertility. May damage the unborn child.
H372	Causes damage to organs through prolonged or repeated exposure.
H410	Very toxic to aquatic life with long lasting effects.

Precautionary statement(s) Prevention

P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.
P260	Do not breathe mist/vapours/spray.
P264	Wash all exposed external body areas thoroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P280	Wear protective gloves, protective clothing, eye protection and face protection.
P273	Avoid release to the environment.
P284	[In case of inadequate ventilation] wear respiratory protection.

Precautionary statement(s) Response

P301+P310	IF SWALLOWED: Immediately call a POISON CENTER/doctor/physician/first aider.
P304+P340	IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P308+P313	IF exposed or concerned: Get medical advice/ attention.
P330	Rinse mouth.
P370+P378	In case of fire: Use alcohol resistant foam or fine spray/water fog to extinguish.
P302+P352	IF ON SKIN: Wash with plenty of water.
P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P337+P313	If eye irritation persists: Get medical advice/attention.
P361+P364	Take off immediately all contaminated clothing and wash it before reuse.
P391	Collect spillage.
P332+P313	If skin irritation occurs: Get medical advice/attention.

Precautionary statement(s) Storage

P403+P233	Store in a well-ventilated place. Keep container tightly closed.
P405	Store locked up.

Precautionary statement(s) Disposal

P501	Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.

No further product hazard information.

SECTION 3 Composition / information on ingredients

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight]	Name
71751-41-2	18	abamectin
872-50-4	35	N-methyl-2-pyrrolidone
Not Available	balance	Ingredients determined not to be hazardous
Legend:	***1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. Classification drawn from C&L; * EU IOELVs available***	

SECTION 4 First aid measures

Description of first aid measures

Eye Contact	If this product comes in contact with the eyes: • Immediately hold eyelids apart and flush the eye continuously with running water. • Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.

Continued...

	▸ Continue flushing until advised to stop by the Poisons Information Centre or a doctor, or for at least 15 minutes. ▸ Transport to hospital or doctor without delay. ▸ Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.
Skin Contact	If skin or hair contact occurs: ▸ Quickly but gently, wipe material off skin with a dry, clean cloth. ▸ Immediately remove all contaminated clothing, including footwear. ▸ Wash skin and hair with running water. Continue flushing with water until advised to stop by the Poisons Information Centre. ▸ Transport to hospital, or doctor.
Inhalation	▸ If fumes or combustion products are inhaled remove from contaminated area. ▸ Lay patient down. Keep warm and rested. ▸ Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures. ▸ Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if necessary. ▸ Transport to hospital, or doctor, without delay.
Ingestion	▸ **IF SWALLOWED, REFER FOR MEDICAL ATTENTION, WHERE POSSIBLE, WITHOUT DELAY.** ▸ For advice, contact a Poisons Information Centre or a doctor. ▸ Urgent hospital treatment is likely to be needed. ▸ In the mean time, qualified first-aid personnel should treat the patient following observation and employing supportive measures as indicated by the patient's condition. ▸ If the services of a medical officer or medical doctor are readily available, the patient should be placed in his/her care and a copy of the SDS should be provided. Further action will be the responsibility of the medical specialist. ▸ If medical attention is not available on the worksite or surroundings send the patient to a hospital together with a copy of the SDS. **Where medical attention is not immediately available or where the patient is more than 15 minutes from a hospital or unless instructed otherwise:** ▸ **INDUCE** vomiting with fingers down the back of the throat, **ONLY IF CONSCIOUS**. Lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. **NOTE:** Wear a protective glove when inducing vomiting by mechanical means.

Indication of any immediate medical attention and special treatment needed

Treat symptomatically.
For abamectin (avermectins):
Toxicity following accidental ingestion may be minimised by emesis-induction within one half hour of exposure. Since abamectin is thought to bind to glutamate-gated chloride ion channels, it is probably wise to avoid drugs that also interact with other ligand-gated chloride channels, including those that enhance GABA activity in patients with potentially toxic abamectin exposure
Avoid drugs that enhance GABA activity (barbiturate, benzodiazepines, valproic acid, etc.).
As in all cases of suspected poisoning, follow the ABCDEs of emergency medicine (airway, breathing, circulation, disability, exposure), then the ABCDEs of toxicology (antidotes, basics, change absorption, change distribution, change elimination).
For poisons (where specific treatment regime is absent):

BASIC TREATMENT

- Establish a patent airway with suction where necessary.
- Watch for signs of respiratory insufficiency and assist ventilation as necessary.
- Administer oxygen by non-rebreather mask at 10 to 15 L/min.
- Monitor and treat, where necessary, for pulmonary oedema.
- Monitor and treat, where necessary, for shock.
- Anticipate seizures.
- **DO NOT** use emetics. Where ingestion is suspected rinse mouth and give up to 200 ml water (5 ml/kg recommended) for dilution where patient is able to swallow, has a strong gag reflex and does not drool.

ADVANCED TREATMENT

- Consider orotracheal or nasotracheal intubation for airway control in unconscious patient or where respiratory arrest has occurred.
- Positive-pressure ventilation using a bag-valve mask might be of use.
- Monitor and treat, where necessary, for arrhythmias.
- Start an IV D5W TKO. If signs of hypovolaemia are present use lactated Ringers solution. Fluid overload might create complications.
- Drug therapy should be considered for pulmonary oedema.
- Hypotension with signs of hypovolaemia requires the cautious administration of fluids. Fluid overload might create complications.
- Treat seizures with diazepam.
- Proparacaine hydrochloride should be used to assist eye irrigation.

BRONSTEIN, A.C. and CURRANCE, P.L.
EMERGENCY CARE FOR HAZARDOUS MATERIALS EXPOSURE: 2nd Ed. 1994

SECTION 5 Firefighting measures

Extinguishing media

- Foam.
- Dry chemical powder.
- BCF (where regulations permit).
- Carbon dioxide.
- Water spray or fog - Large fires only.

Special hazards arising from the substance or mixture

Fire Incompatibility	▸ Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result

Advice for firefighters

Fire Fighting	▸ Alert Fire Brigade and tell them location and nature of hazard. ▸ Wear full body protective clothing with breathing apparatus. ▸ Prevent, by any means available, spillage from entering drains or water course. ▸ Use fire fighting procedures suitable for surrounding area. ▸ **Do not** approach containers suspected to be hot.

Continued...

	‣ Cool fire exposed containers with water spray from a protected location. ‣ If safe to do so, remove containers from path of fire. ‣ Equipment should be thoroughly decontaminated after use.
Fire/Explosion Hazard	‣ Combustible. ‣ Slight fire hazard when exposed to heat or flame. ‣ Heating may cause expansion or decomposition leading to violent rupture of containers. ‣ On combustion, may emit toxic fumes of carbon monoxide (CO). ‣ May emit acrid smoke. ‣ Mists containing combustible materials may be explosive. Combustion products include: ‣ carbon dioxide (CO_2) nitrogen oxides (NOx) ‣ other pyrolysis products typical of burning organic material. May emit poisonous fumes.
HAZCHEM	2X

SECTION 6 Accidental release measures

Personal precautions, protective equipment and emergency procedures

See section 8

Environmental precautions

See section 12

Methods and material for containment and cleaning up

Minor Spills	Environmental hazard - contain spillage. ‣ Remove all ignition sources. ‣ Clean up all spills immediately. ‣ Avoid breathing vapours and contact with skin and eyes. ‣ Control personal contact with the substance, by using protective equipment. ‣ Contain and absorb spill with sand, earth, inert material or vermiculite. ‣ Wipe up. ‣ Place in a suitable, labelled container for waste disposal.
Major Spills	Environmental hazard - contain spillage. ‣ Clear area of personnel and move upwind. ‣ Alert Fire Brigade and tell them location and nature of hazard. ‣ Wear full body protective clothing with breathing apparatus. ‣ Prevent, by any means available, spillage from entering drains or water course. ‣ Stop leak if safe to do so. ‣ Contain spill with sand, earth or vermiculite. ‣ Collect recoverable product into labelled containers for recycling. ‣ Neutralise/decontaminate residue (see Section 13 for specific agent). ‣ Collect solid residues and seal in labelled drums for disposal. ‣ Wash area and prevent runoff into drains. ‣ After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using. ‣ If contamination of drains or waterways occurs, advise emergency services.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

Precautions for safe handling

Safe handling	‣ **DO NOT** allow clothing wet with material to stay in contact with skin ‣ Avoid skin contact, including inhalation. ‣ Wear protective clothing when risk of exposure occurs. ‣ Use in a well-ventilated area. ‣ Prevent concentration in hollows and sumps. ‣ **DO NOT** enter confined spaces until atmosphere has been checked. ‣ **DO NOT** allow material to come in direct contact with human skin or eyes. ‣ **DO NOT** allow material to come in contact with exposed food or food contact surfaces. ‣ Suitable PPE must be worn at all times. ‣ Avoid contact with incompatible materials. ‣ When handling, **DO NOT** eat, drink or smoke. ‣ Keep containers securely sealed when not in use. ‣ Avoid physical damage to containers. ‣ Always wash hands with soap and water after handling. ‣ Work clothes should be laundered separately. Launder contaminated clothing before re-use. ‣ Use good occupational work practice. ‣ Observe manufacturer's storage and handling recommendations contained within this SDS. ‣ Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.
Other information	Consider storage under inert gas. ‣ Store in original containers. ‣ Keep containers securely sealed. ‣ Store in a cool, dry, well-ventilated area. ‣ Store away from incompatible materials and foodstuff containers. ‣ Protect containers against physical damage and check regularly for leaks. ‣ Observe manufacturer's storage and handling recommendations contained within this SDS.

Conditions for safe storage, including any incompatibilities

Suitable container	‣ Lined metal can, lined metal pail/ can. ‣ Plastic pail. ‣ Polyliner drum. ‣ Packing as recommended by manufacturer.

Continued...

	‣ Check all containers are clearly labelled and free from leaks. For low viscosity materials ‣ Drums and jerricans must be of the non-removable head type. ‣ Where a can is to be used as an inner package, the can must have a screwed enclosure. For materials with a viscosity of at least 2680 cSt. (23 deg. C) and solids (between 15 C deg. and 40 deg C.): ‣ Removable head packaging; ‣ Cans with friction closures and ‣ low pressure tubes and cartridges may be used. - Where combination packages are used, and the inner packages are of glass, there must be sufficient inert cushioning material in contact with inner and outer packages *. - In addition, where inner packagings are glass and contain liquids of packing group I and II there must be sufficient inert absorbent to absorb any spillage *. - * unless the outer packaging is a close fitting moulded plastic box and the substances are not incompatible with the plastic.
Storage incompatibility	‣ Avoid reaction with oxidising agents

SECTION 8 Exposure controls / personal protection

Control parameters

Occupational Exposure Limits (OEL)

INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
Australia Exposure Standards	N-methyl-2-pyrrolidone	1-Methyl-2-pyrrolidone	25 ppm / 103 mg/m3	309 mg/m3 / 75 ppm	Not Available	Not Available
Australia Workplace exposure limits for airborne contaminants (WEL list) - Appendix A - Workplace Exposure Limits	N-methyl-2-pyrrolidone	1-Methyl-2-pyrrolidone	20 ppm / 80 mg/m3	Not Available	Not Available	Not Available

MATERIAL DATA

for N-methyl-2-pyrrolidone (NMP):
Reports of skin and eye irritation and chronic headaches have been reported in workers exposed to 1-methyl-2-pyrrolidone. The Australian ES is based on a 10-fold uncertainty factor of the no-observable-adverse-effect level (NOAEL) of 24 ppm where adverse respiratory effects were observed in a 4-week inhalation study in rats.
These exposure guidelines have been derived from a screening level of risk assessment and should not be construed as unequivocally safe limits. ORGS represent an 8-hour time-weighted average unless specified otherwise.
CR = Cancer Risk/10000; UF = Uncertainty factor:
TLV believed to be adequate to protect reproductive health:
LOD: Limit of detection
Toxic endpoints have also been identified as:
D = Developmental; R = Reproductive; TC = Transplacental carcinogen
Jankovic J., Drake F.: A Screening Method for Occupational Reproductive
American Industrial Hygiene Association Journal 57: 641-649 (1996)
For abamectin (avermectins)
CEL TWA: 0.04 mg/m3 [Manufacturer]
(CEL = Chemwatch Exposure Limit)
The acceptable daily intake (ADI) of 0.4 mg/day was derived using an NOAEL of 0.25 mg/kg/day from oral toxicity studies in dogs, adjusting for body weight (50 kg) and by applying a composite uncertainty factor of 30 to account for interindividual variability, interspecies extrapolation and the severity of the critical endpoint (neurotoxicity). The recommended
exposure standard and a wipe test criteria of 0.4 mg/100 cm2 were derived using the ADI.

Exposure controls

Appropriate engineering controls

Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection.
The basic types of engineering controls are:
Process controls which involve changing the way a job activity or process is done to reduce the risk.
Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use.
Employers may need to use multiple types of controls to prevent employee overexposure.

Local exhaust ventilation usually required. If risk of overexposure exists, wear approved respirator. Correct fit is essential to obtain adequate protection. Supplied-air type respirator may be required in special circumstances. Correct fit is essential to ensure adequate protection.
An approved self contained breathing apparatus (SCBA) may be required in some situations.
Provide adequate ventilation in warehouse or closed storage area. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.

Type of Contaminant:	Air Speed:
solvent, vapours, degreasing etc., evaporating from tank (in still air).	0.25-0.5 m/s (50-100 f/min.)
aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, welding, spray drift, plating acid fumes, pickling (released at low velocity into zone of active generation)	0.5-1 m/s (100-200 f/min.)
direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)	1-2.5 m/s (200-500 f/min.)
grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion).	2.5-10 m/s (500-2000 f/min.)

Within each range the appropriate value depends on:

Lower end of the range	Upper end of the range

Continued...

1: Room air currents minimal or favourable to capture	1: Disturbing room air currents
2: Contaminants of low toxicity or of nuisance value only.	2: Contaminants of high toxicity
3: Intermittent, low production.	3: High production, heavy use
4: Large hood or large air mass in motion	4: Small hood-local control only

Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 1-2 m/s (200-400 f/min) for extraction of solvents generated in a tank 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.

Individual protection measures, such as personal protective equipment



Eye and face protection

- Safety glasses with side shields.
- Chemical goggles.[AS/NZS 1337.1, EN166 or national equivalent]
- Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59].

Skin protection

See Hand protection below

Hands/feet protection

- Wear chemical protective gloves, e.g. PVC.
- Wear safety footwear or safety gumboots, e.g. Rubber

The selection of suitable gloves does not only depend on the material, but also on further marks of quality which vary from manufacturer to manufacturer. Where the chemical is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application.
The exact break through time for substances has to be obtained from the manufacturer of the protective gloves and has to be observed when making a final choice.
Personal hygiene is a key element of effective hand care. Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.
Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include:
· frequency and duration of contact,
· chemical resistance of glove material,
· glove thickness and
· dexterity
Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739, AS/NZS 2161.1 or national equivalent).
· When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended.
· When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended.
· Some glove polymer types are less affected by movement and this should be taken into account when considering gloves for long-term use.
· Contaminated gloves should be replaced.
As defined in ASTM F-739-96 in any application, gloves are rated as:
· Excellent when breakthrough time > 480 min
· Good when breakthrough time > 20 min
· Fair when breakthrough time < 20 min
· Poor when glove material degrades
For general applications, gloves with a thickness typically greater than 0.35 mm, are recommended.
It should be emphasised that glove thickness is not necessarily a good predictor of glove resistance to a specific chemical, as the permeation efficiency of the glove will be dependent on the exact composition of the glove material. Therefore, glove selection should also be based on consideration of the task requirements and knowledge of breakthrough times.
Glove thickness may also vary depending on the glove manufacturer, the glove type and the glove model. Therefore, the manufacturers technical data should always be taken into account to ensure selection of the most appropriate glove for the task.
Note: Depending on the activity being conducted, gloves of varying thickness may be required for specific tasks. For example:
· Thinner gloves (down to 0.1 mm or less) may be required where a high degree of manual dexterity is needed. However, these gloves are only likely to give short duration protection and would normally be just for single use applications, then disposed of.
· Thicker gloves (up to 3 mm or more) may be required where there is a mechanical (as well as a chemical) risk i.e. where there is abrasion or puncture potential
Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.

Body protection

See Other protection below

Other protection

- Overalls.
- Eyewash unit.
- Barrier cream.
- Skin cleansing cream.

Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:
"Forsberg Clothing Performance Index".
The effect(s) of the following substance(s) are taken into account in the ***computer-generated*** selection:
Apparent Abamectin 18 Miticide/Insecticide

Material	CPI
BUTYL	A
PE/EVAL/PE	A

Respiratory protection

Full face respirator with supplied air.

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required. Degree of protection varies with both face-piece and Class of filter; the nature of protection varies with Type of filter.

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 10 x ES	AK-AUS	-	AK-PAPR-AUS / Class 1

Continued...

NATURAL RUBBER	B
PVA	B

* CPI - Chemwatch Performance Index
A: Best Selection
B: Satisfactory; may degrade after 4 hours continuous immersion
C: Poor to Dangerous Choice for other than short term immersion
NOTE: As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -
* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

Ansell Glove Selection

Glove — *In order of recommendation*
MICROFLEX® 93-260
AlphaTec® 38-612
AlphaTec® 53-001
AlphaTec® 58-005
AlphaTec® Solvex® 37-175
BioClean™ Fusion (Sterile) S-BFAP
MICROFLEX® Diamond Grip® MF-300
MICROFLEX® LifeStar EC™ 93-868
MICROFLEX® SafeGrip™ SG-375
BioClean™ Emerald BENS

The suggested gloves for use should be confirmed with the glove supplier.

up to 50 x ES	-	AK-AUS / Class 1	-
up to 100 x ES	-	AK-2	AK-PAPR-2 ^

^ - Full-face
A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

- Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content.
- The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too high, or that the mask is not properly fitted. Because of these limitations, only restricted use of cartridge respirators is considered appropriate.
- Cartridge performance is affected by humidity. Cartridges should be changed after 2 hr of continuous use unless it is determined that the humidity is less than 75%, in which case, cartridges can be used for 4 hr. Used cartridges should be discarded daily, regardless of the length of time used

SECTION 9 Physical and chemical properties

Information on basic physical and chemical properties

Appearance	Clear colourless to pale yellow coloured liquid.

Physical state	Liquid	**Relative density (Water = 1)**	1
Odour	Characteristic	**Partition coefficient n-octanol / water**	Not Available
Odour threshold	Not Available	**Auto-ignition temperature (°C)**	Not Available
pH (as supplied)	Not Available	**Decomposition temperature (°C)**	Not Available
Melting point / freezing point (°C)	Not Available	**Viscosity (mm2/s)**	Not Available
Initial boiling point and boiling range (°C)	Not Available	**Molecular weight (g/mol)**	Not Applicable
Flash point (°C)	70	**Taste**	Not Available
Evaporation rate	Not Available	**Explosive properties**	Not Available
Flammability	Combustible.	**Oxidising properties**	Not Available
Upper Explosive Limit (%)	Not Available	**Surface Tension (dyn/cm or mN/m)**	Not Available
Lower Explosive Limit (%)	Not Available	**Volatile Component (%vol)**	Not Available
Vapour pressure (kPa)	Not Available	**Gas group**	Not Available
Solubility in water	Partly miscible	**pH as a solution (1%)**	Not Available
Vapour density (Air = 1)	Not Available	**VOC g/L**	Not Available
Heat of Combustion (kJ/g)	Not Available	**Ignition Distance (cm)**	Not Available
Flame Height (cm)	Not Available	**Flame Duration (s)**	Not Available
Enclosed Space Ignition Time Equivalent (s/m3)	Not Available	**Enclosed Space Ignition Deflagration Density (g/m3)**	Not Available

SECTION 10 Stability and reactivity

Reactivity	See section 7
Chemical stability	▸ Unstable in the presence of incompatible materials. ▸ Product is considered stable. ▸ Hazardous polymerisation will not occur.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7

Continued...

Hazardous decomposition products	See section 5

SECTION 11 Toxicological information

Information on toxicological effects

a) Acute Toxicity	There is sufficient evidence to classify this material as acutely toxic.
b) Skin Irritation/Corrosion	There is sufficient evidence to classify this material as skin corrosive or irritating.
c) Serious Eye Damage/Irritation	There is sufficient evidence to classify this material as eye damaging or irritating
d) Respiratory or Skin sensitisation	Based on available data, the classification criteria are not met.
e) Mutagenicity	Based on available data, the classification criteria are not met.
f) Carcinogenicity	Based on available data, the classification criteria are not met.
g) Reproductivity	There is sufficient evidence to classify this material as toxic to reproductivity
h) STOT - Single Exposure	There is sufficient evidence to classify this material as toxic to specific organs through single exposure
i) STOT - Repeated Exposure	There is sufficient evidence to classify this material as toxic to specific organs through repeated exposure
j) Aspiration Hazard	Based on available data, the classification criteria are not met.

Inhaled	Inhalation of vapours or aerosols (mists, fumes), generated by the material during the course of normal handling, may produce severely toxic effects; these may be fatal. Evidence shows, or practical experience predicts, that the material produces irritation of the respiratory system, in a substantial number of individuals, following inhalation. In contrast to most organs, the lung is able to respond to a chemical insult by first removing or neutralising the irritant and then repairing the damage. The repair process, which initially evolved to protect mammalian lungs from foreign matter and antigens, may however, produce further lung damage resulting in the impairment of gas exchange, the primary function of the lungs. Respiratory tract irritation often results in an inflammatory response involving the recruitment and activation of many cell types, mainly derived from the vascular system. Inhalation of vapours may cause drowsiness and dizziness. This may be accompanied by narcosis, reduced alertness, loss of reflexes, lack of coordination and vertigo. Inhalation of high vapour concentrations of N-methyl-2-pyrrolidone (NMP) may produce mucous membrane irritation, headache, giddiness, mental confusion and nausea. Fatalities were not recorded following inhalation of 180-200 mg/m3 for 2 hours by mice and following a 6 hour exposure to saturated vapours by rats. Laboratory animals exposed to concentrations of 50 ppm for 8 hours daily for 20 days or 370 ppm for 6 hours daily for 10 days showed no gross or histopathological abnormalities There were no deaths recorded in rats inhaling 5.73 mg/l abamectin (avermectins); the animals also exhibited normal behaviour and there were no changes in body weights Inhalation of dusts, generated by the material, during the course of normal handling, may produce severely toxic effects; these may be fatal.
Ingestion	Severely toxic effects may result from the accidental ingestion of the material; animal experiments indicate that ingestion of less than 5 gram may be fatal or may produce serious damage to the health of the individual. There have been several reports of acute human exposure incidents with abamectin containing formulations. Abamectin is a mixture of avermectins. Clinical symptoms of severe abamectin intoxication include mydriasis, sedation, emesis, tremors, convulsions, coma and death. One successful suicide attempt was reported (estimated lethal doses 3.6 to 4.5 grams of abamectin). Systemic reactions in humans may include fever, rash and lymph-node pain or swelling. Ocular reactions have been minimal. In monkeys, emesis occurred following a single oral dosage of 2 mg/kg; mydriasis was seen at 24 mg/kg indicating a dose-response curve is flatter in monkeys than in rodents. Macrolides comprise a large group of antibiotics derived from ***Streptomyces spp.*** and other microbial and plant species**,** having in common a macrocyclic lactone ring to which one or more sugars are attached. They are all weak bases. The most common side effect produced by the family of macrolide antibiotics is gastrointestinal discomfort. Supra-infections may occur although these are rare. Several macrolides produced allergic sensitisation but, again, these are rare. Symptoms include watery eyes, shortness of breath, nasal congestion, choking, coughing and wheezing. Allergic skin reactions have also occurred. Exposure to at least one member of the family, erythromycin, at high concentrations, has produced reversible deafness (ototoxicity). Systemic reactions including fever, rash, and lymph-node pain or swelling have been produced by the avermectin group. Ivermectin has produced ataxia (incoordination), lethargy, bradypnea (slowed breathing), vomiting, mydriasis (dilated pupils), sedation, tremors and death in animals. The avermectin group (anthelmintics, insecticides and acaricides) mediate the transmission of gamma-butyric acid (GABA), an inhibitory neurotransmitter, in mammals thus causing paralysis. Hepatotoxic effects with transient disturbances and jaundice have resulted from the use of oleandomycin. Transient alterations in heart rate/ rhythm have also been produced by several members of the family (notably tilmicosin). Heart muscle degeneration, characterised by small areas of cell death have also been reported in animals exposed to tilmicosin. Cross-resistance is often observed between the macrolide, lincosamide and streptogramin group of antibiotics. Macrolides should not be taken with colchicine as it may lead to colchicine toxicity. Symptoms of colchicine toxicity include gastrointestinal upset, fever, myalgia, pancytopenia, and organ failure The combination of some macrolides and statins (used for lowering cholesterol) is not advisable and can lead to debilitating myopathy. This is because some macrolides (clarithromycin and erythromycin, not azithromycin) are potent inhibitors of the cytochrome P450 system, particularly of CYP3A4. Macrolides, mainly erythromycin and clarithromycin, also have a class effect of QT prolongation, which can lead to torsades de pointes. Macrolides exhibit enterohepatic recycling; that is, the drug is absorbed in the gut and sent to the liver, only to be excreted into the duodenum in bile from the liver. This can lead to a buildup of the product in the system, thereby causing nausea. In infants the use of erythromycin has been associated with pyloric stenosis. Some macrolides are also known to cause cholestasis, a condition where bile cannot flow from the liver to the duodenum. One study found an association between erythromycin use during infancy and developing (infantile hypertrophic pyloric stenosis.(IHPS - which can progress to near-complete obstruction of the gastric outlet, leading to forceful vomiting in infants) . However, no significant association was found between macrolides use during pregnancy or breastfeeding Considered an unlikely route of entry in commercial/industrial environments The liquid may produce considerable gastrointestinal discomfort and may be harmful or toxic if swallowed. Ingestion may result in nausea, pain and vomiting. Vomit entering the lungs by aspiration may cause potentially lethal chemical pneumonitis
Skin Contact	Skin contact with the material may produce toxic effects; systemic effects may result following absorption. Evidence exists, or practical experience predicts, that the material either produces inflammation of the skin in a substantial number of individuals following direct contact, and/or produces significant inflammation when applied to the healthy intact skin of animals, for up to four hours, such inflammation being present twenty-four hours or more after the end of the exposure period. Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At

Continued...

	the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidermis. The material may accentuate any pre-existing dermatitis condition Prolonged contact with N-methyl-2-pyrrolidone (NMP) reportedly causes severe dermatitis with redness, cracking, swelling, blisters and oedema. An instance of severe skin irritation after a few days work with NMP shows latex rubber gloves as giving insufficient protection. A review article casts doubts on reliability of animal single patch tests, i.e Draize tests. [Irritant Cutaneous Reaction to NMP, Contact Dermatitis 27: 148-150, 1992] In rats and rabbits, dermal exposure to abamectin, under occluded conditions for 24 hours, at a dosage of 300 and 2000 mg/kg, respectively, produced tremors, ataxia, decreased activity, weight loss and death. Dermal penetration of abamectin in monkeys was determined to be less than 1% Abamectin did not show potential to produce skin sensitisation in the guinea pig maximisation test. Open cuts, abraded or irritated skin should not be exposed to this material Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected. Absorption by skin may readily exceed vapour inhalation exposure. Symptoms for skin absorption are the same as for inhalation.
Eye	Direct contact with the liquid N-methyl-2-pyrrolidone (NMP) may produce painful burning or stinging of the eyes and lids, watering and inflammation of the conjunctiva and temporary corneal clouding. Evidence exists, or practical experience predicts, that the material may cause eye irritation in a substantial number of individuals and/or may produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals. Repeated or prolonged eye contact may cause inflammation characterised by a temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur.
Chronic	Long-term exposure to respiratory irritants may result in disease of the airways involving difficult breathing and related systemic problems. Toxic: danger of serious damage to health by prolonged exposure through inhalation, in contact with skin and if swallowed. Serious damage (clear functional disturbance or morphological change which may have toxicological significance) is likely to be caused by repeated or prolonged exposure. As a rule the material produces, or contains a substance which produces severe lesions. Such damage may become apparent following direct application in subchronic (90 day) toxicity studies or following sub-acute (28 day) or chronic (two-year) toxicity tests. There is sufficient evidence to establish a causal relationship between human exposure to the material and impaired fertility There is sufficient evidence to provide a strong presumption that human exposure to the material may result in impaired fertility on the basis of: - clear evidence in animal studies of impaired fertility in the absence of toxic effects, or evidence of impaired fertility occurring at around the same dose levels as other toxic effects but which is not a secondary non-specific consequence of other toxic effects. There is sufficient evidence to establish a causal relationship between human exposure to the material and subsequent developmental toxic effects in the off-spring. There is sufficient evidence to provide a strong presumption that human exposure to the material may result in developmental toxicity, generally on the basis of: - clear results in appropriate animal studies where effects have been observed in the absence of marked maternal toxicity, or at around the same dose levels as other toxic effects but which are not secondary non-specific consequences of the other toxic effects. Exposure to the material may cause concerns for humans owing to possible developmental toxic effects, generally on the basis that results in appropriate animal studies provide strong suspicion of developmental toxicity in the absence of signs of marked maternal toxicity, or at around the same dose levels as other toxic effects but which are not a secondary non-specific consequence of other toxic effects. The teratogenic potential, subchronic and long term inhalation toxicity of N-methyl-2-pyrrolidone (NMP has been studied in rats. No evidence of nephrotoxicity was seen. No carcinogenic effects were observed. Very high doses are embryotoxic to rats and mice. Reproductive effects have been reported in animals. Prolonged or repeated use of antibiotics, at therapeutic doses, may produce bacterial resistance for some types of bacteria. Prolonged use may result in the overgrowth of non-susceptible organisms (i.e. super- infection). ***Clostridium difficile*** associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agent and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of ***C. difficile.*** ***C. difficile*** produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of ***C. difficile*** cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use or exposure. Repeated or long-term occupational exposure is likely to produce cumulative health effects involving organs or biochemical systems.

Apparent Abamectin 18 Miticide/Insecticide	**TOXICITY**	**IRRITATION**
	Not Available	Not Available
abamectin	**TOXICITY**	**IRRITATION**
	dermal (rat) LD50: >330 mg/kg[2]	Not Available
	Inhalation (Rat) LC50: 1.1 mg/L4h[2]	
	Oral (Mouse) LD50; 13.6 mg/kg[2]	
N-methyl-2-pyrrolidone	**TOXICITY**	**IRRITATION**
	Dermal (rabbit) LD50: 8000 mg/kg[2]	Eye (Human): 530ppm/30M - Mild
	Inhalation (Rat) LC50: 3.1-8.8 mg/l4h[2]	Eye (Rodent - rabbit): 0.1mL
	Oral (Rat) LD50: 3914 mg/kg[2]	Eye (Rodent - rabbit): 100mg - Moderate
		Eye: adverse effect observed (irritating)[1]
		Skin: adverse effect observed (irritating)[1]

Legend:	***1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2. Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances***

Apparent Abamectin 18 Miticide/Insecticide	Most people have very few pyrroles in their system at any given time; certain individuals, however, have an unusually high number of pyrroles in their bodies, resulting in a condition known as pyroluria. Pyroluria is becoming more and more prevalent both in children with ADHD and autism and in the general population. It is a little known condition; it was first given the name ‘mauve factor.

Continued...

	Pyroluria is a genetically acquired chemical imbalance in which the body produces an abnormally large number of pyrroles. A pyrrole is a chemical that is the by-product of haemoglobin synthesis and have no known function in the body; they are normally excreted in the urine. Pyroluria occurs when the pyrroles bind to pyroxidine (vitamin B6) and zinc, causing these vital nutrients to be excreted from the body in large amounts. Deficiencies of B6 and zinc are associated with a wide range of emotional and psychiatric problems. Vitamin B6 is critical for the production of neurotransmitters and deficiencies can have a profound effect on both mental and physical health. Nervousness, extreme irritability, anxiety, depression, short-term memory problems, and explosive anger have all been linked to Proluria. A large percentage of patients with psychiatric disorders such as schizophrenia exhibit high levels of pyrroles; emotionally dysregulated children and those with an excessive alcohol intake also tend to have an abnormally high pyrrole count. In addition, zinc deficiencies have been associated with a number of physiological disorders, including poor immune function, poor growth, and delayed sexual development. Because zinc and B6 are so important to both our overall physical and mental health, identifying and treating this devastating condition is critical. Included in this condition are changes to fatty acid metabolism which lead to high levels of an omega 6 fatty acid call arachidonic acid. Current research shows that neurological disorders such as ASD as well as psychiatric disorders have a high rate of remission with pyrrole treatment. Pyrrole Disorder can also be triggered by a traumatic event and high stress levels and is also often part of the picture for PDD, ODD, Tics, Tourette s Syndrome, Depression, and Bipolar Disorder. Treatment of Pyroluria consists of a replacement of zinc and vitamin B6. Because the treatment is replacing deficiencies not pharmacologic, it needs to be titrated to individual requirements. Common symptoms associated with Pyrrole Disorder in children (may not include all symptoms): · Sleep problems, particularly taking a long time to fall asleep and waking up easily at night · Sensory sensitivity i.e. to the labels on clothes, to specific fabrics – e.g. 'feels prickly , to noises. · Anxiety. (Anxiety can contribute to digestive upsets such as IBS) · Poor tolerance of stress · Depression, pessimistic outlook, mood swings, emotional lability · Anger and violence out of proportion to the situation, including rage · Poor functioning of the digestive system, including poor absorption of nutrients as well as food sensitivities · Low immunity – constantly suffering with coughs and colds · Motion sickness · Reading and learning problems · Poor memory · Slow growth · Delayed puberty · Unpleasant body odour · Stretch marks on skin · Pain in joints and extremities · Sweet fruity breath and body odour, problems with sugar metabolism, allergies
ABAMECTIN	Oral (rat) LD50: 8.7-12.8 mg/kg (14 day) * ADI 0.0001 mg/kg Toxicity Class EPA IV Non-mutagenic in the Ames test ADI: 0.4 mg/day * [Manufacturer] Convulsions recorded.
N-METHYL-2-PYRROLIDONE	A substance (or part of a group of chemical substances) of very high concern (SVHC) - or product containing an SVHC: It is proposed that use within the European Union be subject to authorisation under the REACH Regulation.Indeed, listing of a substance as an SVHC by the European Chemicals Agency (ECHA) is the first step in the procedure for authorisation or restriction of use of a chemical. The criteria are given in article 57 of the REACH Regulation. A substance may be proposed as an SVHC if it meets one or more of the following criteria: ▸ it is carcinogenic *; ▸ it is mutagenic *; ▸ it is toxic for reproduction *; ▸ it is persistent, bioaccumulative and toxic (PBT substances); ▸ it is very persistent and very bioaccumulative (vPvB substances); ▸ there is "scientific evidence of probable serious effects to human health or the environment which give rise to an equivalent level of concern"; such substances are identified on a case-by-case basis. * Collectively described as CMR substances The "equivalent concern" criterion is significant because it is this classification which allows substances which are, for example, neurotoxic, endocrine-disrupting or otherwise present an unanticipated environmental health risk to be regulated under REACH] Simply because a substance meets one or more of the criteria does not necessarily mean that it will be proposed as an SVHC. Many such substances are already subject to restrictions on their use within the European Union, such as those in Annex XVII of the REACH Regulation SVHCs are substances for which the current restrictions on use (where these exist) might be insufficient. There are three priority groups for assessment: ▸ PBT substances and vPvB substances; ▸ substances which are widely dispersed during use; ▸ substances which are used in large quantities.
Apparent Abamectin 18 Miticide/Insecticide & N-METHYL-2-PYRROLIDONE	Asthma-like symptoms may continue for months or even years after exposure to the material ends. This may be due to a non-allergic condition known as reactive airways dysfunction syndrome (RADS) which can occur after exposure to high levels of highly irritating compound. Main criteria for diagnosing RADS include the absence of previous airways disease in a non-atopic individual, with sudden onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. Other criteria for diagnosis of RADS include a reversible airflow pattern on lung function tests, moderate to severe bronchial hyperreactivity on methacholine challenge testing, and the lack of minimal lymphocytic inflammation, without eosinophilia. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. On the other hand, industrial bronchitis is a disorder that occurs as a result of exposure due to high concentrations of irritating substance (often particles) and is completely reversible after exposure ceases. The disorder is characterized by difficulty breathing, cough and mucus production. for N-methyl-2-pyrrolidone (NMP): **Acute toxicity:** In rats, NMP is absorbed rapidly after inhalation, oral, and dermal administration, distributed throughout the organism, and eliminated mainly by hydroxylation to polar compounds, which are excreted via urine. About 80% of the administered dose is excreted as NMP and NMP metabolites within 24 h. A probably dose-dependent yellow coloration of the urine in rodents is observed. The major metabolite is 5-hydroxy-***N***-methyl-2-pyrrolidone. Studies in humans show comparable results. Dermal penetration through human skin has been shown to be very rapid. NMP is rapidly biotransformed by hydroxylation to 5-hydroxy-***N***-methyl-2-pyrrolidone, which is further oxidized to ***N***-methylsuccinimide; this intermediate is further hydroxylated to 2-hydroxy-***N***-methylsuccinimide. These metabolites are all colourless. The excreted amounts of NMP metabolites in the urine after inhalation or oral intake represented about 100% and 65% of the administered doses, respectively. NMP has a low potential for skin irritation and a moderate potential for eye irritation in rabbits. Repeated daily doses of 450 mg/kg body weight administered to the skin caused painful and severe haemorrhage and eschar formation in rabbits. These adverse effects have not been seen in workers occupationally exposed to pure NMP, but they have been observed after dermal exposure to NMP used in cleaning processes. No sensitisation potential has been observed. In acute toxicity studies in rodents, NMP showed low toxicity. Uptake of oral, dermal, or inhaled acutely toxic doses causes functional disturbances and depressions in the central nervous system. Local irritation effects were observed in the respiratory tract when NMP was inhaled and in the pyloric and gastrointestinal tracts after oral administration. In humans, there was no irritative effect in the respiratory system after an 8-h exposure to 50 mg/m3. **Repeat dose toxicity:** There is no clear toxicity profile of NMP after multiple administration. In a 28-day dietary study in rats, a compound-related decrease in body weight gain was observed in males at 1234 mg/kg body weight and in females at 2268 mg/kg body weight.

Continued...

	Testicular degeneration and atrophy in males and thymic atrophy in females were observed at these dose levels. The no-observed-adverse-effect level (NOAEL) was 429 mg/kg body weight in males and 1548 mg/kg body weight in females. In a 28-day intubation study in rats, a dose-dependent increase in relative liver and kidney weights and a decrease in lymphocyte count in both sexes were observed at 1028 mg/kg body weight. The NOAEL in this study was 514 mg/kg body weight. In another rat study, daily dietary intake for 90 days caused decreased body weights at doses of 433 and 565 mg/kg body weight in males and females, respectively. There were also neurobehavioural effects at these dose levels. The NOAELs in males and females were 169 and 217 mg/kg body weight, respectively. The toxicity profile after exposure to airborne NMP depends strongly on the ratio of vapour to aerosol and on the area of exposure (i.e., head-only or whole-body exposure). Because of higher skin absorption for the aerosol, uptake is higher in animals exposed to aerosol than in those exposed to vapour at similar concentrations. Studies in female rats exposed head only to 1000 mg/m3 showed only minor nasal irritation, but massive mortality and severe effects on major organs were observed when the females were whole-body exposed to the same concentration of coarse droplets at high relative humidity. Several studies in rats following repeated exposure to NMP at concentrations between 100 and 1000 mg/m3 have shown systemic toxicity effects at the lower dose levels. In most of the studies, the effects were not observed after a 4-week observation period. In rats, exposure to 3000 mg NMP/m3 (head only) for 6 h/day, 5 days/week, for 13 weeks caused a decrease in body weight gain, an increase in erythrocytes, haemoglobin, haematocrit, and mean corpuscular volume, decreased absolute testis weight, and cell loss in the germinal epithelium of the testes. The NOAEL was 500 mg/m3. There are no data in humans after repeated-dose exposure. **Carcinogenicity:** NMP did not show any clear evidence for carcinogenicity in rats exposed to concentrations up to 400 mg/m3 in a long-term inhalation study. **Genotoxicity:** The mutagenic potential of NMP is weak. Only a slight increase in the number of revertants was observed when tested in a ***Salmonella*** assay with base-pair substitution strains. NMP has been shown to induce aneuploidy in yeast ***Saccharomyces cerevisiae*** cells. No investigations regarding mutagenicity in humans were available. **Reproductive toxicity:** In a two-generation reproduction study in rats, whole-body exposure of both males and females to 478 mg/m3 of NMP vapour for 6 h/day, 7 days/week, for a minimum of 100 days (pre-mating, mating, gestation, and lactation periods) resulted in a 7% decrease in fetal weight in the F1 offspring. A 4-11% transient, non-dose-dependent decrease was observed in the average pup weight at all exposure levels tested (41, 206, and 478 mg/m3). **Developmental toxicity:** When NMP was administered dermally, developmental toxicity was registered in rats at 750 mg/kg body weight. The observed effects were increased preimplantation losses, decreased fetal weights, and delayed ossification. The NOAEL for both developmental effects and maternal toxicity (decreased body weight gain) was 237 mg/kg body weight. Inhalation studies in rats (whole-body exposure) demonstrated developmental toxicity as increased preimplantation loss without significant effect on implantation rate or number of live fetuses at 680 mg/m3 and behavioural developmental toxicity at 622 mg/m3. In an inhalation study (whole-body exposure), the NOAEL for maternal effects was 100 mg/m3, and the NOAEL for developmental effects was 360 mg/m3. A tolerable inhalation concentration, 0.3 mg/m3, based on mortality and organ damage, is expected to be protective against any possible reproductive toxicity. Similarly, an oral tolerable intake of 0.6 mg/kg body weight per day, based on a 90-day study, is expected to provide adequate protection against possible reproductive effects. Because of non-existent data on the exposure of the general population and very limited information on occupational exposure, no meaningful risk characterisation can be performed
Apparent Abamectin 18 Miticide/Insecticide & ABAMECTIN	No significant acute toxicological data identified in literature search. For avermectins: Technical avermectin exhibits high mammalian acute toxicity. In vertebrates, the effects occur via poisoning of the central nervous system (CNS) through reactions at the receptor for the inhibitory neurotransmitter GABA. The avermectins open the GABAA receptor chloride channel by binding to the GABA recognition site (receptor protein) and act as partial agonists.. Chloride ions then flow into the postsynaptic neuron. This chloride permeability increase can significantly hyperpolarize (make more negative) the membrane potential, which has a dampening effect on nerve impulse firing. There is also a reversible dose-dependent increase in chloride ion permeability in response to very low doses of avermectins. In GABA-insensitive neurons with no inhibitory innervation, the avermectins induce an irreversible increase in chloride ion conductance through interacting with voltage-dependent chloride channels. Avermectin intoxication in mammals begins with hyperexcitability, tremors, and incoordination and later develops into ataxia and coma-like sedation. This is similar to the mode of action of ethanol and barbiturates and benzodiazepine sedatives However, the avermectins are less specific in their action and can affect a variety of other ligand- and voltage-gated chloride channels. The general safety of the avermectins depends on the presence of an intact P-glycoprotein blood-brain barrier Avermectin is not considered to be mutagenic and does not sensitise skin. It is not readily absorbed by mammals and the majority of the residue is excreted in the faeces within 2 days. The 24-month rat chronic feeding/ oncogenicity study and 94-week mouse chronic toxicity oncogenicity study were negative for oncogenic potential. The results of a series of developmental toxicity studies (rat, rabbit, mouse) have been evaluated and showed that avermectin B1 produces developmental toxicity (cleft palate) in the CF1 mouse. Toxicology data were also evaluated for the delta-8,9-isomer of avermectin B1 which is a plant photodegradate that can range between 5 and 20 percent of the residue on/in cottonseed. This isomer possesses avermectin-like toxicological activity. It was concluded that the delta 8,9-isomer also produces developmental toxicity (cleft palate) in mice, but not in rats. In addition to avermectin and its delta 8,9-isomer, toxicology data were also evaluated for the "polar degradates" of avermectin, which constitute a large percentage (up to 70%) of the total residue on cottonseed. Review of the toxicology data indicated that these polar degradates do not possess avermectin-like toxicological activity and for this reason need not be included in the tolerance expression for residues in/on cottonseed. Abamectin (a mixture of avermectin isomers) is a reproductive toxin in laboratory animals at doses which are acutely toxic to the mother. In development toxicity studies with abamectin, cleft palates were seen in mice and rabbits and clubbing of the forepaws was seen in rabbits. The no-observed-adverse-effect-level (NOAEL) for maternal and developmental toxicity in rabbits was 1 mg/kg/day. In CF-1 mice, a strain recognised to be particularly sensitive to avermectins, the NOAEL for maternal toxicity was 0.05 mg/kg/day and the NOAEL for malformations was 0.2 mg/kg/day. Studies show that the sensitivity of a subpopulation of CF-1 mice to avermectins is due to the absence of a transmembrane P-glycoprotein, a significant component of the blood-brain interface that normally acts as a non-selective protective barrier in a wide range of species including humans. CF-1 mice are therefore an unlikely candidate for assessing human risk. No evidence of developmental toxicity was seen in oral studies in rats in the absence of maternal toxicity (NOAEL = 1.6 mg/kg/day). In a rat multigenerational reproduction study, pup toxicity and deaths were seen at 0.4 mg/kg/day (NOAEL = 0.12 mg/kg/day). Neonatal rats are not an appropriate model for assessing human risk in humans because (a) rat milk has a greater fat content than human breast milk and abamectin concentrates in fat; (b) on a weight basis, the neonatal rat consumes significantly greater quantities of milk than the newborn human and(c) the blood brain barrier in rodents is formed post-natally (as evidenced by low P-glycoprotein levels) while in humans this membrane is formed pre-natally. Ivermectin, a close structural analogue, has been used extensively in the treatment of human onchocerciasis at an oral therapeutic dose of 0.2 mg/kg, without serious drug-related effects. Despite its wide usage in animals and humans, ivermectin does dot appear to produce birth defects. Abamectin is non-mutagenic in the Ames test and the micronucleus test. Dietary carcinogenicity studies in mice and rats showed negative results. In a 14-week oral study in monkeys no effects were seen at 0.2, 0.5 or 1.0 mg/kg/day; emesis was seen at 2.0 mg/kg/day; delayed pupillary obstruction at 6 and 8 mg/kg/day and mydriasis at 12 mg/kg/day. In chronic oral toxicity, abamectin produced decreased body weight gain in mice (no-observed-adverse-effect-level (NOAEL) = 1.5 mg/kg/day); tremors in rats (NOAEL = 1.5 mg/kg/day), weight loss, tremors, mydriasis, liver and gall bladder changes and death in dogs (NOAEL = 0.25 mg/kg/day); and emesis, mydriasis and sedation in monkeys (NOAL = 1 mg/kg/day).

Acute Toxicity	✔	**Carcinogenicity**	✘
Skin Irritation/Corrosion	✔	**Reproductivity**	✔
Serious Eye Damage/Irritation	✔	**STOT - Single Exposure**	✔

Continued...

Respiratory or Skin sensitisation	✗	**STOT - Repeated Exposure**	✓
Mutagenicity	✗	**Aspiration Hazard**	✗

Legend: ✗ *– Data either not available or does not fill the criteria for classification*
✓ *– Data available to make classification*

SECTION 12 Ecological information

Toxicity

Apparent Abamectin 18 Miticide/Insecticide

Endpoint	Test Duration (hr)	Species	Value	Source
Not Available	Not Available	Not Available	Not Available	Not Available

abamectin

Endpoint	Test Duration (hr)	Species	Value	Source
EC50	72h	Algae or other aquatic plants	4.4mg/l	4
EC50	48h	Crustacea	<0.001mg/L	4
EC50(ECx)	48h	Crustacea	<0.001mg/L	4
EC50	96h	Algae or other aquatic plants	7.31mg/l	4
LC50	96h	Fish	0.002-0.006mg/L	4

N-methyl-2-pyrrolidone

Endpoint	Test Duration (hr)	Species	Value	Source
EC50	72h	Algae or other aquatic plants	>500mg/l	1
EC50	48h	Crustacea	ca.4897mg/l	1
LC50	96h	Fish	464mg/l	1
NOEC(ECx)	504h	Crustacea	12.5mg/l	2

Legend: ***Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 3. US EPA, Ecotox database - Aquatic Toxicity Data 4. ECETOC Aquatic Hazard Assessment Data 5. NITE (Japan) - Bioconcentration Data 6. METI (Japan) - Bioconcentration Data 7. Vendor Data 8. User defined data***

Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.
Do NOT allow product to come in contact with surface waters or to intertidal areas below the mean high water mark. Do not contaminate water when cleaning equipment or disposing of equipment wash-waters.
Wastes resulting from use of the product must be disposed of on site or at approved waste sites.
Toxic to bees.
For macrocyclic lactones (MLs) antibiotics and insecticides, typically avermectins (including ivermectins), milbemycins and spinosyns.
The environmental impacts of many macrocyclic lactones make them substances of high concern particularly with larval instars of invertebrates. Studies have also shown that susceptibility varies with life cycle stage and impacts can be mitigated by using MLs when these stages are not present.
The physical/chemical properties of MLs indicate that, once they have entered the environment, they can persist for extended periods of time at concentrations high enough to exert toxic impacts. To date, pasture ecosystems have been of greatest concern. In terrestrial systems, the entry of MLs into the environment is through livestock excretion on pasture soils. MLs enter marine systems in the faeces of farmed salmon, as well as through uneaten food that settles in sediments
MLs may enter the terrestrial compartment via spreading of manure from intensively reared animals on arable land or by excretion of dung by animals on pastures. Several models were developed to estimate the environmental burden (predicted environmental concentration, PEC) of MLs that accumulates in environment, both in the terrestrial and aquatic environment Ivermectin was selected as a case study compound within the project ERAPharm (Environmental Risk Assessment of Pharmaceuticals) The ERA clearly demonstrated unacceptable risks for all investigated environmental compartments and hence suggested the necessity of reassessing ivermectin-containing products. Based on this case study, several gaps in the existing guidelines for ERA of pharmaceuticals were shown and improvements have been suggested]. The risk characterization using long-term effects data for aquatic and sediment organisms (D. magna and C. riparius) as required according to VICH 2004 resulted in an indication of risk for these compartments.
While the Risk quotient (RQ) for sediment organisms was between 2.1 and 36, the RQ for daphnids was >105, indicating a very high risk for aquatic invertebrates
for N-methyl-2-pyrrolidinone (NMP):
log Kow : -0.44-0.1
Environmental Fate
NMP may enter the environment as emissions to the atmosphere, as the substance is volatile and widely used as a solvent, or it may be released to water as a component of municipal and industrial wastewaters. The substance is mobile in soil, and leaching from landfills is thus a possible route of contamination of groundwater.
In air, NMP is expected to be removed by wet deposition or by photochemical reactions with hydroxyl radicals. As the substance is completely miscible in water, it is not expected to adsorb to soil, sediments, or suspended organic matter or to bioconcentrate. NMP is not degraded by chemical hydrolysis. Data from screening tests on the biodegradability of NMP show that the substance is rapidly biodegraded.
This material is not expected to persist in the environment. It is water soluble and is expected to have low volatility. Hydrolysis is not expected to be an important factor in the environmental fate process for this material.
Persistence and Degradability
Biodegradation: BOD (Modified MITI Method) = 73% (28 days). BOD (Modified MITI Method) = 92% (14 days). This material is expected to be readily biodegradable.
Bioaccumulation: BCF = 0.16. This material is not expected to bioaccumulate
Ecotoxicity
This material is expected to be non-hazardous to aquatic species.
Fish LC50 (96 h): bluegill. 832 mg/l, fathead minnow 1072 mg/l; rainbow trout 3048 mg/l
Daphnia magna EC50 (24 h): > 1000 mg/l
Algae EC50 (72 h): Scenedesmus subspicatus > 500 mg/l

For avermectin:
log Kow 4 (abamectin)
Environmental fate:
Avermectin undergoes rapid photolysis, is readily degraded by soil microorganisms and, due to its binding properties and low water solubility, is expected to exhibit little or no potential for leaching. Both aquatic and terrestrial studies confirm the rapid
degradation of abamectin (a mixture of avermectins) in the environment and its lack of accumulation and persistence. Abamectin is not degraded by sewage treatment organisms nor does it affect them.
Abamectin does not bioconcentrate in fish and is not taken up from soil into plants. Bioaccumulation does not occur
Avermectin is stable to hydrolysis at ph 5, 7, and 9 and thus is not expected to hydrolyse in the environment. It photodegrades rapidly in water and soil with half-lives of less than 12 hours and 1 day respectively.
Abamectin hydrolyses rapidly in water when exposed to strong light and is metabolised in the soil (half-life 20-47 days)
Soil metabolism studies conducted in darkness indicate degradation of avermectin does occur with a half-life of 2 weeks to 2 months under aerobic conditions. Anaerobic degradation is slower. It is not expected to accumulate in fish. Avermectin's solubility in water is determined to be 7.8 ppb. The field dissipation study indicates that avermectin,

Continued...

when applied in the bait formulation directly to the soil, dissipates with a half-life of about a week but may persist longer if the bait is shaded. Due to its binding properties and low water solubility, avermectin is expected to exhibit little or no potential for leaching. However avermectin has shown conflicting results in soil thin- layer chromatographic (TLC) (immobile) and soil column studies.
Abamectin binds tightly to soil (Koc >4000)
Polar degradates of avermectins are largely unidentified, but are thought to be non-toxic
Ecotoxicity:
Bird Acute oral LD50: bobwhite quail >2000 mg/kg; LC50 3102 ppm
Bird Dietary LC50: mallard duck 383 ppm
Fish LC50: bluegill 9.6 ppb; rainbow trout 3.2 ppb; fathead minnow 15 ppb
Daphnia LC50 0.22 ppb
Mysid shrimp LC50: 0.02 ppb
Avermectin is extremely toxic to mammals and aquatic invertebrates and highly toxic to fish and bees. Avermectin is relatively non-toxic to birds. Based upon terrestrial residue analysis, aquatic runoff modeling and cluster analysis it appears that certain endangered species may be impacted by the use of avermectin on cotton.
For abamectin (mixture of avermectins)
Bird Acute oral LD50: 84.6 mg/kg; bobwhite quail >2000 mg/kg
Bird Dietary LC50 (8 days): bobwhite quail 3.1 mg/kg
Fish LC50 (96 h): for rainbow trout 3.2 ug/l; bluegill sunfish 9.6 ug/l; channel catfish 24 ug/l; carp 42 ug/l
Daphnia EC50 (48 h) 0.34 ppb
Other aquatic spp:LC50 (96 h) for pink shrimp 1.6 ppb; mysid shrimp 0.022 ppb; blue crab 153 ppb
Risk Quotient (RQ) =Exposure/Toxicity where
· Exposure refers to estimated environmental concentration (EEC).
· Toxicity refers to an effect level or endpoint obtained from eco-toxicity testing, such as an LC50 or NOEC
After the risk quotient(s) is calculated, it is compared to US EPA's Level of Concern (LOC). If RQ is less than LOC, it is generally regarded that the risk is acceptable.
The table below describes different types of risk quotients for aquatic species and EPA's level of concern. An LOC is a policy tool that the Agency uses to interpret the risk quotient and to analyze potential risk to non-target organisms and the need to consider regulatory action.

Risk Presumptions	Risk Quotient	LOC
Acute High Risk	EEC/ lowest LC50 or EC50	0.5
Acute Restricted Use	EEC/ lowest LC50 or EC50	0.1
Acute Endangered Species	EEC/ lowest LC50 or EC50	0.05
Chronic Risk	EEC/ lowest LC50 or EC50	1.0

DO NOT discharge into sewer or waterways.

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
N-methyl-2-pyrrolidone	LOW	LOW

Bioaccumulative potential

Ingredient	Bioaccumulation
abamectin	MEDIUM (LogKOW = 4.4)
N-methyl-2-pyrrolidone	LOW (BCF = 0.16)

Mobility in soil

Ingredient	Mobility
N-methyl-2-pyrrolidone	LOW (Log KOC = 20.94)

SECTION 13 Disposal considerations

Waste treatment methods

Product / Packaging disposal	▸ Containers may still present a chemical hazard/ danger when empty. ▸ Return to supplier for reuse/ recycling if possible. Otherwise: ▸ If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill. ▸ Where possible retain label warnings and SDS and observe all notices pertaining to the product. Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to laws operating in their area. In some areas, certain wastes must be tracked. A Hierarchy of Controls seems to be common - the user should investigate: ▸ Reduction ▸ Reuse ▸ Recycling ▸ Disposal (if all else fails) This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. If it has been contaminated, it may be possible to reclaim the product by filtration, distillation or some other means. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling or reuse may not always be appropriate. ▸ **DO NOT** allow wash water from cleaning or process equipment to enter drains. ▸ It may be necessary to collect all wash water for treatment before disposal. ▸ In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first. ▸ Where in doubt contact the responsible authority. ▸ Recycle wherever possible or consult manufacturer for recycling options. ▸ Consult State Land Waste Authority for disposal. ▸ Bury or incinerate residue at an approved site. ▸ Recycle containers if possible, or dispose of in an authorised landfill.

SECTION 14 Transport information

Labels Required

Continued...

	
Marine Pollutant	
HAZCHEM	2X

Land transport (ADG)

14.1. **UN number or ID number**	2902
14.2. **UN proper shipping name**	PESTICIDE, LIQUID, TOXIC, N.O.S. (contains N-methyl-2-pyrrolidone and abamectin)
14.3. **Transport hazard class(es)**	Class: 6.1 Subsidiary Hazard: Not Applicable
14.4. **Packing group**	III
14.5. **Environmental hazard**	Environmentally hazardous
14.6. **Special precautions for user**	Special provisions: 61 223 274 Limited quantity: 5 L

Air transport (ICAO-IATA / DGR)

14.1. **UN number**	2902
14.2. **UN proper shipping name**	Pesticide, liquid, toxic, n.o.s. * (contains N-methyl-2-pyrrolidone and abamectin)
14.3. **Transport hazard class(es)**	ICAO/IATA Class: 6.1 ICAO / IATA Subsidiary Hazard: Not Applicable ERG Code: 6L
14.4. **Packing group**	III
14.5. **Environmental hazard**	Environmentally hazardous
14.6. **Special precautions for user**	Special provisions: A3 A4 Cargo Only Packing Instructions: 663 Cargo Only Maximum Qty / Pack: 220 L Passenger and Cargo Packing Instructions: 655 Passenger and Cargo Maximum Qty / Pack: 60 L Passenger and Cargo Limited Quantity Packing Instructions: Y642 Passenger and Cargo Limited Maximum Qty / Pack: 2 L

Sea transport (IMDG-Code / GGVSee)

14.1. **UN number**	2902
14.2. **UN proper shipping name**	PESTICIDE, LIQUID, TOXIC, N.O.S. (contains N-methyl-2-pyrrolidone and abamectin)
14.3. **Transport hazard class(es)**	IMDG Class: 6.1 IMDG Subsidiary Hazard: Not Applicable
14.4. **Packing group**	III
14.5 **Environmental hazard**	Marine Pollutant
14.6. **Special precautions for user**	EMS Number: F-A, S-A Special provisions: 61 223 274 Limited Quantities: 5 L

14.7. Maritime transport in bulk according to IMO instruments

14.7.1. Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

14.7.2. Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group
abamectin	Not Applicable

Continued...

Product name	Group
N-methyl-2-pyrrolidone	Not Applicable

14.7.3. Transport in bulk in accordance with the IGC Code

Product name	Ship Type
abamectin	Not Applicable
N-methyl-2-pyrrolidone	Not Applicable

SECTION 15 Regulatory information

Safety, health and environmental regulations / legislation specific for the substance or mixture

abamectin is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 4
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 7
Chemical Footprint Project - Chemicals of High Concern List

N-methyl-2-pyrrolidone is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6
Australian Inventory of Industrial Chemicals (AIIC)
Chemical Footprint Project - Chemicals of High Concern List
Responsible Business Alliance Industry Focus Process Chemicals Policy (RBA IFPC Policy) - Table 1: Industry Focus Process Chemicals List

Additional Regulatory Information

Not Applicable

National Inventory Status

National Inventory	Status
Australia - AIIC / Australia Non-Industrial Use	No (abamectin)
Canada - DSL	No (abamectin)
Canada - NDSL	No (abamectin; N-methyl-2-pyrrolidone)
China - IECSC	No (abamectin)
Colombia - Colombia National Industrial Chemicals Inventory	No (abamectin; N-methyl-2-pyrrolidone)
Europe - EINEC / ELINCS / NLP	No (abamectin)
Japan - ENCS	No (abamectin)
Korea - KECI	Yes
New Zealand - NZIoC	Yes
Philippines - PICCS	No (abamectin)
USA - TSCA	TSCA Inventory 'Active' substance(s) (N-methyl-2-pyrrolidone); No (abamectin)
Taiwan - TCSI	Yes
Mexico - INSQ	Yes
Vietnam - NCI	Yes
Russia - FBEPH	No (abamectin)
UAE - Control List (Banned/Restricted Substances)	No (N-methyl-2-pyrrolidone)
Legend:	***Yes = All CAS declared ingredients are on the inventory*** ***No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.***

SECTION 16 Other information

Revision Date	12/11/2026
Initial Date	12/11/2026

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

Continued...

- PC—TWA: Permissible Concentration-Time Weighted Average
- PC—STEL: Permissible Concentration-Short Term Exposure Limit
- IARC: International Agency for Research on Cancer
- ACGIH: American Conference of Governmental Industrial Hygienists
- STEL: Short Term Exposure Limit
- TEEL: Temporary Emergency Exposure Limit。
- IDLH: Immediately Dangerous to Life or Health Concentrations
- ES: Exposure Standard
- OSF: Odour Safety Factor
- NOAEL: No Observed Adverse Effect Level
- LOAEL: Lowest Observed Adverse Effect Level
- TLV: Threshold Limit Value
- LOD: Limit Of Detection
- OTV: Odour Threshold Value
- BCF: BioConcentration Factors
- BEI: Biological Exposure Index
- DNEL: Derived No-Effect Level
- PNEC: Predicted no-effect concentration
- MARPOL: International Convention for the Prevention of Pollution from Ships
- IMSBC: International Maritime Solid Bulk Cargoes Code
- IGC: International Gas Carrier Code
- IBC: International Bulk Chemical Code

- AIIC: Australian Inventory of Industrial Chemicals
- DSL: Domestic Substances List
- NDSL: Non-Domestic Substances List
- IECSC: Inventory of Existing Chemical Substance in China
- EINECS: European INventory of Existing Commercial chemical Substances
- ELINCS: European List of Notified Chemical Substances
- NLP: No-Longer Polymers
- ENCS: Existing and New Chemical Substances Inventory
- KECI: Korea Existing Chemicals Inventory
- NZIoC: New Zealand Inventory of Chemicals
- PICCS: Philippine Inventory of Chemicals and Chemical Substances
- TSCA: Toxic Substances Control Act
- TCSI: Taiwan Chemical Substance Inventory
- INSQ: Inventario Nacional de Sustancias Químicas
- NCI: National Chemical Inventory
- FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances

This document is copyright.
Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.
TEL (+61 3) 9572 4700.

end of SDS